# GRM1

## Overview
The GRM1 gene encodes the glutamate metabotropic receptor 1 (mGluR1), a G-protein coupled receptor (GPCR) that plays a pivotal role in the central nervous system by modulating synaptic transmission and plasticity. As a member of the metabotropic glutamate receptor family, mGluR1 is characterized by its seven-transmembrane domain structure, which is typical of GPCRs, and its ability to form disulfide-linked homodimers. This receptor is predominantly expressed in the brain, particularly in the cerebellum, where it is crucial for motor control and learning processes. mGluR1's activation triggers intracellular signaling cascades that influence various cellular processes, including calcium release and protein kinase activation. Mutations in the GRM1 gene have been linked to neurological disorders such as spinocerebellar ataxias and psychiatric conditions like schizophrenia, as well as certain cancers, highlighting its clinical significance (Nicoletti2011Metabotropic; Martino2012Metabotropic; Protasova2023Genetic).

## Structure
The GRM1 gene encodes the glutamate metabotropic receptor 1 (mGluR1), a G-protein coupled receptor (GPCR) involved in neurotransmission. The primary structure of mGluR1 consists of 1194 amino acids, including a signal peptide from amino acids 1 to 18 and seven transmembrane regions spanning amino acids 593 to 840 (Park2011A). The secondary structure features a seven-transmembrane (7TM) domain, which is typical of GPCRs, and includes alpha-helices (Wu2014Structure).

The tertiary structure of mGluR1 is characterized by a 7TM domain that forms a parallel dimer, with the dimer interface primarily mediated through helix I. Cholesterol molecules are observed packed against hydrophobic residues on the extracellular side of helices I and II, aiding in dimer formation (Wu2014Structure). The extracellular loop 2 (ECL2) adopts a β-hairpin conformation, connected to helix III through a conserved disulfide bond (Wu2014Structure).

In terms of quaternary structure, mGluR1 forms disulfide-linked homodimers, with the ligand-binding region (LBR) exhibiting a 'clamshell'-like shape composed of two domains, LB1 and LB2 (Kunishima2000Structural). The receptor undergoes conformational changes upon ligand binding, transitioning between open and closed states, which are crucial for receptor activation (Kunishima2000Structural). The receptor's structure is further stabilized by glutamate binding, which affects the separation of the transmembrane and intracellular regions (Kunishima2000Structural).

## Function
The GRM1 gene encodes the metabotropic glutamate receptor 1 (mGluR1), a G-protein coupled receptor primarily involved in modulating synaptic transmission and plasticity in the central nervous system. mGluR1 is predominantly expressed in the brain, with high levels in the cerebellum, particularly in Purkinje cells, where it plays a crucial role in synaptic plasticity, motor control, and learning processes such as long-term depression (LTD) at parallel fiber-Purkinje cell synapses (Nicoletti2011Metabotropic; Protasova2023Genetic).

Activation of mGluR1 leads to the stimulation of phospholipase Cβ, resulting in the production of inositol-1,4,5-trisphosphate (Ins-1,4,5-P3) and diacylglycerol (DAG). This signaling cascade releases calcium from intracellular stores and activates protein kinase C, influencing various cellular processes (Nicoletti2011Metabotropic). mGluR1 also modulates voltage-sensitive calcium channels and negatively regulates certain potassium channels, impacting neuronal excitability and synaptic transmission (Nicoletti2011Metabotropic).

In addition to its role in synaptic plasticity, mGluR1 is involved in the regulation of neurotransmitter release and is essential for normal cerebellar function and coordination. Mutations in GRM1 can lead to cerebellar ataxia, highlighting its importance in motor control (Rossi2009The; Protasova2023Genetic).

## Clinical Significance
Mutations in the GRM1 gene, which encodes the metabotropic glutamate receptor 1 (mGluR1), are associated with several neurological and psychiatric disorders. In the context of spinocerebellar ataxias, GRM1 mutations can lead to autosomal dominant spinocerebellar ataxia type 44 (SCA44) and autosomal recessive spinocerebellar ataxia type 13 (SCAR13). The autosomal recessive form is particularly severe, often resulting in psychomotor developmental delay, intellectual disability, and severe motor function impairment, while the autosomal dominant form generally has a milder progression (Protasova2023Genetic; Wang2023SCA44).

GRM1 mutations have also been implicated in psychiatric conditions such as schizophrenia. Studies have shown that rare nonsynonymous single nucleotide polymorphisms (nsSNPs) in GRM1 among schizophrenia patients are more likely to be deleterious, affecting receptor function and potentially contributing to the pathogenesis of the disorder (Ayoub2012Deleterious).

In cancer, GRM1 has been identified as an oncogene in epithelial cells, with its expression linked to aggressive melanoma and other cancers. Altered GRM1 expression can lead to enhanced cell proliferation and tumorigenicity, suggesting its potential as a therapeutic target in cancer treatment (Martino2012Metabotropic).

## Interactions
GRM1, also known as metabotropic glutamate receptor 1, is involved in various protein interactions that influence its function and signaling pathways. GRM1 interacts with G proteins, which are heterotrimeric proteins consisting of alpha and beta/gamma subunits. Upon activation, GRM1 can couple to different G proteins, such as Ga q/11 and Ga s, leading to the activation of signaling pathways like phospholipase C (PLC) and the MAPK cascade (Mar�n2004Involvement).

GRM1 also interacts with Homer proteins, which contain PDZ domains. These interactions regulate GRM1's constitutive activity and affect receptor location, clustering, and cell surface expression (Mar�n2004Involvement). The C-terminal domain of GRM1 contains a proline-rich Homer1 binding motif, crucial for protein-protein interactions and complex formation with downstream molecules (Ali2014Identification).

In the context of melanoma, GRM1 can transactivate receptor tyrosine kinases (RTKs) such as the platelet-derived growth factor (PDGF) receptor, potentially through coupling to Ga i/o proteins. This transactivation involves the activation of Src family tyrosine kinases, which further stimulate MAPK signaling (Mar�n2004Involvement).


## References


[1. (Ali2014Identification) Shafat Ali, Mojgan Shourideh, and Shahriar Koochekpour. Identification of novel grm1 mutations and single nucleotide polymorphisms in prostate cancer cell lines and tissues. PLoS ONE, 9(7):e103204, July 2014. URL: http://dx.doi.org/10.1371/journal.pone.0103204, doi:10.1371/journal.pone.0103204. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0103204)

2. (Wang2023SCA44) SCA44- and SCAR13-associatedGRM1mutations affect metabotropic glutamate receptor 1 function through distinct mechanisms. This article has 0 citations.

[3. (Protasova2023Genetic) Maria S. Protasova, Tatiana V. Andreeva, Sergey A. Klyushnikov, Sergey N. Illarioshkin, and Evgeny I. Rogaev. Genetic variant in grm1 underlies congenital cerebellar ataxia with no obvious intellectual disability. International Journal of Molecular Sciences, 24(2):1551, January 2023. URL: http://dx.doi.org/10.3390/ijms24021551, doi:10.3390/ijms24021551. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24021551)

[4. (Mar�n2004Involvement) Yar� E. Mar�n and Suzie Chen. Involvement of metabotropic glutamate receptor�1, a g protein coupled receptor, in melanoma development. Journal of Molecular Medicine, 82(11):735–749, August 2004. URL: http://dx.doi.org/10.1007/s00109-004-0566-8, doi:10.1007/s00109-004-0566-8. This article has 43 citations.](https://doi.org/10.1007/s00109-004-0566-8)

[5. (Ayoub2012Deleterious) Mohammed Akli Ayoub, Dora Angelicheva, David Vile, David Chandler, Bharti Morar, Juleen A. Cavanaugh, Peter M. Visscher, Assen Jablensky, Kevin D. G. Pfleger, and Luba Kalaydjieva. Deleterious grm1 mutations in schizophrenia. PLoS ONE, 7(3):e32849, March 2012. URL: http://dx.doi.org/10.1371/journal.pone.0032849, doi:10.1371/journal.pone.0032849. This article has 58 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0032849)

[6. (Martino2012Metabotropic) J J Martino, B A Wall, E Mastrantoni, B J Wilimczyk, S N La Cava, K Degenhardt, E White, and S Chen. Metabotropic glutamate receptor 1 (grm1) is an oncogene in epithelial cells. Oncogene, 32(37):4366–4376, October 2012. URL: http://dx.doi.org/10.1038/onc.2012.471, doi:10.1038/onc.2012.471. This article has 45 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2012.471)

[7. (Park2011A) Hyun-Kyung Park, Su Kang Kim, Sung Hoon Lim, Woo Yong Ahn, Geum-hee Gwak, and Dae Jean Jo. A polymorphism (rs2073287) of glutamate receptor, metabotropic 1 (grm1) is associated with an increased risk of stroke in korean population. Molecular &amp; Cellular Toxicology, 7(3):243–250, September 2011. URL: http://dx.doi.org/10.1007/s13273-011-0030-0, doi:10.1007/s13273-011-0030-0. This article has 2 citations.](https://doi.org/10.1007/s13273-011-0030-0)

[8. (Rossi2009The) Pia Irene Anna Rossi, Carlotta Maria Vaccari, Alessandra Terracciano, Laura Doria-Lamba, Sabrina Facchinetti, Manuela Priolo, Carmen Ayuso, Laura Jorge, Stefania Gimelli, Filippo Maria Santorelli, Roberto Ravazzolo, and Aldamaria Puliti. The metabotropic glutamate receptor 1, grm1: evaluation as a candidate gene for inherited forms of cerebellar ataxia. Journal of Neurology, 257(4):598–602, November 2009. URL: http://dx.doi.org/10.1007/s00415-009-5380-3, doi:10.1007/s00415-009-5380-3. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00415-009-5380-3)

[9. (Nicoletti2011Metabotropic) F. Nicoletti, J. Bockaert, G.L. Collingridge, P.J. Conn, F. Ferraguti, D.D. Schoepp, J.T. Wroblewski, and J.P. Pin. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology, 60(7–8):1017–1041, June 2011. URL: http://dx.doi.org/10.1016/j.neuropharm.2010.10.022, doi:10.1016/j.neuropharm.2010.10.022. This article has 516 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.neuropharm.2010.10.022)

[10. (Wu2014Structure) Huixian Wu, Chong Wang, Karen J. Gregory, Gye Won Han, Hyekyung P. Cho, Yan Xia, Colleen M. Niswender, Vsevolod Katritch, Jens Meiler, Vadim Cherezov, P. Jeffrey Conn, and Raymond C. Stevens. Structure of a class c gpcr metabotropic glutamate receptor 1 bound to an allosteric modulator. Science, 344(6179):58–64, April 2014. URL: http://dx.doi.org/10.1126/science.1249489, doi:10.1126/science.1249489. This article has 465 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.1249489)

[11. (Kunishima2000Structural) Naoki Kunishima, Yoshimi Shimada, Yuji Tsuji, Toshihiro Sato, Masaki Yamamoto, Takashi Kumasaka, Shigetada Nakanishi, Hisato Jingami, and Kosuke Morikawa. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature, 407(6807):971–977, October 2000. URL: http://dx.doi.org/10.1038/35039564, doi:10.1038/35039564. This article has 1023 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/35039564)